BRPI0519737A2 - composiÇÕes e mÉtodos para promover a cura de feridas e a regeneraÇço de tecidos - Google Patents

composiÇÕes e mÉtodos para promover a cura de feridas e a regeneraÇço de tecidos

Info

Publication number
BRPI0519737A2
BRPI0519737A2 BRPI0519737-6A BRPI0519737A BRPI0519737A2 BR PI0519737 A2 BRPI0519737 A2 BR PI0519737A2 BR PI0519737 A BRPI0519737 A BR PI0519737A BR PI0519737 A2 BRPI0519737 A2 BR PI0519737A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
wound healing
tissue regeneration
promote wound
Prior art date
Application number
BRPI0519737-6A
Other languages
English (en)
Inventor
Robert Gourdie
Gautam Ghatnekar
Jane Jourdan
Original Assignee
Musc Found For Res Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Musc Found For Res Dev filed Critical Musc Found For Res Dev
Publication of BRPI0519737A2 publication Critical patent/BRPI0519737A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • C07K14/43581—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Abstract

COMPOSIÇÕES E MÉTODOS PARA PROMOVER A CURA DE FERIDAS E A REGENERAÇçO DE TECIDOS. São aqui providos composições e métodos para uso na promoção da cura de feridas e da regeneração de tecidos após danos ao tecido de um sujeito.
BRPI0519737-6A 2004-12-21 2005-12-20 composiÇÕes e mÉtodos para promover a cura de feridas e a regeneraÇço de tecidos BRPI0519737A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63836604P 2004-12-21 2004-12-21
US67179605P 2005-04-15 2005-04-15
PCT/US2005/046442 WO2006069181A2 (en) 2004-12-21 2005-12-20 Compositions and methods for promoting wound healing and tissue regeneration

Publications (1)

Publication Number Publication Date
BRPI0519737A2 true BRPI0519737A2 (pt) 2009-01-27

Family

ID=36593626

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519737-6A BRPI0519737A2 (pt) 2004-12-21 2005-12-20 composiÇÕes e mÉtodos para promover a cura de feridas e a regeneraÇço de tecidos

Country Status (17)

Country Link
US (9) US7786074B2 (pt)
EP (4) EP1827480B1 (pt)
JP (2) JP5243040B2 (pt)
KR (1) KR101236450B1 (pt)
AU (1) AU2005319155B2 (pt)
BR (1) BRPI0519737A2 (pt)
CA (1) CA2593979C (pt)
DK (2) DK2377546T3 (pt)
ES (1) ES2620363T3 (pt)
HU (1) HUE038099T2 (pt)
IL (2) IL184045A (pt)
NO (1) NO342964B1 (pt)
NZ (1) NZ556541A (pt)
PL (1) PL2289535T3 (pt)
RU (2) RU2438696C2 (pt)
SG (1) SG158153A1 (pt)
WO (1) WO2006069181A2 (pt)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8658203B2 (en) * 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
WO2005107712A1 (en) 2004-05-03 2005-11-17 Hermes Biosciences, Inc. Liposomes useful for drug delivery
EP1827480B1 (en) 2004-12-21 2016-11-09 MUSC Foundation For Research Development Compositions and methods for promoting wound healing and tissue regeneration
US9408381B2 (en) 2004-12-21 2016-08-09 Musc Foundation For Research Development Alpha Connexin c-Terminal (ACT) peptides for use in transplant
WO2006134494A2 (en) * 2005-02-03 2006-12-21 Coda Therapeutics Limited Anti-connexin compounds and therapeutic uses thereof
AU2016203204A1 (en) * 2005-02-03 2016-06-09 Coda Therapeutics Limited Anti-connexin compounds and uses thereof
RU2542471C2 (ru) 2006-11-15 2015-02-20 Коуда Терапьютикс, Инк. Улучшенные способы и композиции для заживления ран
US8883190B2 (en) * 2006-12-01 2014-11-11 Wake Forest University Health Sciences Urologic devices incorporating collagen inhibitors
CA2672220A1 (en) 2006-12-11 2008-06-19 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
JP5552048B2 (ja) * 2007-06-21 2014-07-16 ムスク ファンデーション フォー リサーチ ディベロップメント 加齢性黄斑変性を治療するためのアルファコネキシンｃ末端（ａｃｔ）ペプチド
DK2211873T3 (da) 2007-10-22 2012-11-19 Amorphical Ltd Stabil, amorf calciumcarbonat, der omfatter phosphorylerede aminosyrer
AU2008335717A1 (en) 2007-12-11 2009-06-18 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
US20100279921A1 (en) * 2007-12-11 2010-11-04 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
EP2237786A2 (en) 2007-12-21 2010-10-13 Coda Therapeutics, Inc. Use of inhibitors of connexin43 for treatment of fibrotic conditions
US9035037B2 (en) 2007-12-21 2015-05-19 Coda Therapeutics, Inc. Medical devices
JP2011507855A (ja) * 2007-12-21 2011-03-10 コーダ セラピューティクス， インコーポレイテッド 外科的癒着の治療のための、単独のまたは抗コネキシンポリヌクレオチドと組み合わせた抗コネキシンペプチドの使用
GB0803352D0 (en) 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
WO2009148552A2 (en) * 2008-06-02 2009-12-10 Kansas State University Research Foundation Methods and compositions for treating disease
US9050070B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8793075B2 (en) 2008-10-31 2014-07-29 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9060926B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9060931B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US8221480B2 (en) * 2008-10-31 2012-07-17 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US9072799B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8849441B2 (en) 2008-10-31 2014-09-30 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
US8762067B2 (en) 2008-10-31 2014-06-24 The Invention Science Fund I, Llc Methods and systems for ablation or abrasion with frozen particles and comparing tissue surface ablation or abrasion data to clinical outcome data
US8798932B2 (en) 2008-10-31 2014-08-05 The Invention Science Fund I, Llc Frozen compositions and methods for piercing a substrate
US9060934B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US9050317B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9072688B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8545856B2 (en) 2008-10-31 2013-10-01 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US8788211B2 (en) 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Method and system for comparing tissue ablation or abrasion data to data related to administration of a frozen particle composition
JP2012509153A (ja) * 2008-11-20 2012-04-19 ライフセル コーポレーション 傍ストーマヘルニアの治療及び予防のための方法
US20100286762A1 (en) * 2009-03-18 2010-11-11 Musc Foundation For Research Development Compositions and Methods for Ameliorating Clinical Electrical Disturbances
US8609409B2 (en) 2009-06-04 2013-12-17 Clemson University Methods and compositions for cell culture platform
US8680182B2 (en) 2009-06-04 2014-03-25 Clemson University Research Foundation Methods for promoting the revascularization and reenervation of CNS lesions
US20110038921A1 (en) * 2009-08-13 2011-02-17 Clemson University Research Foundation Methods and compositions for temporal release of agents from a biodegradable scaffold
DK2536340T3 (en) * 2010-02-19 2019-02-11 Lifecell Corp ABDOMINAL WAVE TREATMENT DEVICES
CA2695337A1 (en) * 2010-03-04 2011-09-04 Ian De Belle Compositions and methods for inhibition of hiv
ES2369101B2 (es) * 2010-05-07 2012-08-02 Universidade De Santiago De Compostela Sistema farmacéutico acuoso para la administración de fármacos en las uñas.
BR112012029611A2 (pt) 2010-05-21 2017-07-25 Merrimack Pharmaceuticals Inc proteína de fusão biespecífica, composição farmacêutica, método de tratamento de dano ao tecido em um indivíduo, método de promoção da regeração ou sobrevivência do tecido em um indivíduo e molécula de ácido nucleico
RU2468795C1 (ru) * 2011-05-10 2012-12-10 Государственное образовательное учреждение высшего профессионального образования "Самарский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации Сорбционное, антимикробное и дезодорирующее лекарственное средство для наружного применения
BR122020015748B1 (pt) * 2011-10-08 2021-06-15 Next Science IP Holdings Pty Ltd Composições antimicrobianas e métodos empregando as mesmas
EP2793964B1 (en) 2011-12-20 2019-03-20 LifeCell Corporation Sheet tissue products
BR112014014975B1 (pt) 2011-12-20 2019-06-25 Lifecell Corporation Produto de tecido, e método para produzir uma composição de tecido
US9271821B2 (en) 2012-01-24 2016-03-01 Lifecell Corporation Elongated tissue matrices
NZ629769A (en) 2012-03-01 2016-09-30 Firststring Res Inc Topical gels containing alpha connexin c-terminal (act) peptides
US10689609B2 (en) 2012-03-15 2020-06-23 Flodesign Sonics, Inc. Acoustic bioreactor processes
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US10322949B2 (en) 2012-03-15 2019-06-18 Flodesign Sonics, Inc. Transducer and reflector configurations for an acoustophoretic device
US9745548B2 (en) 2012-03-15 2017-08-29 Flodesign Sonics, Inc. Acoustic perfusion devices
US9752113B2 (en) 2012-03-15 2017-09-05 Flodesign Sonics, Inc. Acoustic perfusion devices
US10737953B2 (en) 2012-04-20 2020-08-11 Flodesign Sonics, Inc. Acoustophoretic method for use in bioreactors
BR112014026088B1 (pt) 2012-04-24 2019-11-05 Lifecell Corp produto de tratamento de tecidos
JP2015515282A (ja) * 2012-04-25 2015-05-28 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 創傷治癒および組織修復のための組成物および方法
TWI474831B (zh) 2012-09-14 2015-03-01 Univ Taipei Medical 免疫調節蛋白於促進傷口癒合或組織損傷治療的用途
US20140112959A1 (en) 2012-10-18 2014-04-24 MiCal Pharmaceuticals LLC - H Series, a Series of MiCal Pharmaceuticals LLC, a Multi-Division Limite Topical steroid composition and method
US20160166637A1 (en) * 2013-08-02 2016-06-16 Virginia Tech Intellectual Properties, Inc. Methods of treating a cancer through targeted disruption of alpha connexin 43-zonula occludens-1 (zo-1) interaction
US9745569B2 (en) 2013-09-13 2017-08-29 Flodesign Sonics, Inc. System for generating high concentration factors for low cell density suspensions
CA2935960C (en) 2014-01-08 2023-01-10 Bart Lipkens Acoustophoresis device with dual acoustophoretic chamber
RU2549987C1 (ru) * 2014-06-17 2015-05-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации Средство для ускорения заживления ран и регенерации тканей
US9744483B2 (en) 2014-07-02 2017-08-29 Flodesign Sonics, Inc. Large scale acoustic separation device
CN114010788A (zh) 2014-08-22 2022-02-08 奥克兰联合服务有限公司 通道调节剂
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US10758565B2 (en) 2015-06-04 2020-09-01 Amorphical Ltd. Compositions of amorphous calcium carbonate for inhalation, sublingual or buccal administration
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
RU2732567C2 (ru) 2015-10-16 2020-09-21 Ипсен Биофарм Лтд. Стабилизированные фармацевтические композиции камптотецина
WO2017180862A1 (en) * 2016-04-13 2017-10-19 Northeast Ohio Medical University Gpnmb compositions for treatment of skin wounds
US11433116B2 (en) * 2016-04-14 2022-09-06 Cedars-Sinai Medical Center GJA1 isoforms protect against metabolic stress
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
EP3503908A1 (en) * 2016-08-23 2019-07-03 The Cleveland Clinic Foundation Cancer treatment using cx26 blocking peptides
EP3529347A1 (en) 2016-10-19 2019-08-28 Flodesign Sonics, Inc. Affinity cell extraction by acoustics
IL294615A (en) 2016-10-25 2022-09-01 Amorphical Ltd Amorphous calcium carbonate for the treatment of leukemia
RU2646792C1 (ru) * 2016-12-13 2018-03-07 Акаев Ислам Умарович Средство для лошадей, обладающее регенеративной активностью
WO2018151823A1 (en) * 2017-02-16 2018-08-23 Firststring Research, Inc. Composition and methods for preventing radiation injury and promoting tissue regeneration
JP2020517714A (ja) 2017-04-28 2020-06-18 オークランド ユニサービシズ リミテッド 処置方法および新規構築物
WO2018209169A1 (en) * 2017-05-12 2018-11-15 Ohio State Innovation Foundation Peptides and methods for treating neurodegenerative disorders
EP3650032A4 (en) * 2017-07-07 2021-04-14 Lipobiolab Corporation COMPOSITION FOR THE RELIEF AND TREATMENT OF BURNS AND WOUNDS
US11344603B2 (en) 2017-07-19 2022-05-31 Auckland Uniservices Limited Cytokine modulation
CN107446018B (zh) * 2017-08-07 2020-07-17 温州千瑞生物科技有限公司 促进伤口愈合的肽及其应用
SG11202003907WA (en) 2017-12-14 2020-05-28 Flodesign Sonics Inc Acoustic transducer drive and controller
BR112021004731A2 (pt) * 2018-09-12 2021-09-08 Firststring Research, Inc. Formulações de nanopartículas e métodos de uso para peptídeos de terminal-c alfa conexina.
AU2020311900A1 (en) * 2019-07-08 2022-01-27 Xequel Bio, Inc. Compositions and methods for preserving organ transplants
ES2804039A1 (es) * 2019-07-30 2021-02-02 Fund Profesor Novoa Santos Fragmentos peptidicos de cx43 para su uso como agentes senoliticos
CN110606872B (zh) * 2019-10-12 2022-06-21 珠海市雅莎医疗器械有限公司 一种促皮肤创伤修复的抗氧化多肽oa-gl17及其制备方法与应用
KR102251640B1 (ko) 2019-11-27 2021-05-17 서울대학교산학협력단 지방세포 분화 촉진용 펩타이드 및 이를 포함하는 지방세포 분화 촉진용 조성물
KR20210104319A (ko) 2020-02-17 2021-08-25 노태성 궤양 치료를 위한 조성물
CA3174333A1 (en) * 2020-04-07 2021-10-14 Gautam Ghatnekar Compositions and methods for treating complications of viral infections and other respiratory disorders
US20230218716A1 (en) 2020-05-06 2023-07-13 Ohio State Innovation Foudation Compositions and methods for treating atrial fibrillation
EP4340937A1 (en) 2021-05-21 2024-03-27 Emblation Limited Microwave treatment of tissue

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (pt) 1968-10-17 1970-08-24
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
AU6131086A (en) 1985-07-05 1987-01-30 Whitehead Institute For Biomedical Research Epithelial cells expressing foreign genetic material
JPS62209523A (ja) 1986-03-11 1987-09-14 Fuji Photo Film Co Ltd 感光材料
ATE152169T1 (de) 1988-02-05 1997-05-15 Whitehead Biomedical Inst Modifizierte hepatozyten und deren anwendung
WO1990002806A1 (en) 1988-09-01 1990-03-22 Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
US5234809A (en) 1989-03-23 1993-08-10 Akzo N.V. Process for isolating nucleic acid
US6261834B1 (en) 1991-11-08 2001-07-17 Research Corporation Technologies, Inc. Vector for gene therapy
FR2739621B1 (fr) 1995-10-05 1997-12-05 Centre Nat Rech Scient Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives
ATE300959T1 (de) 1999-01-27 2005-08-15 Becker David Dr Formulierungen enthaltend antisense nukleotide spezifisch für connexine
JP2002543825A (ja) * 1999-05-14 2002-12-24 アーバー ビータ コーポレイション 造血細胞内分子相互作用
US7250397B2 (en) 2000-02-23 2007-07-31 Zealand Pharma A/S Antiarrhythmic peptides
AU2002239336A1 (en) 2000-11-10 2002-06-03 Arbor Vita Corporation Molecular interactions in hematopoietic cells
US7364750B2 (en) * 2001-04-30 2008-04-29 The University Of British Columbia Autogene nucleic acids encoding a secretable RNA polymerase
US6867283B2 (en) 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
US20050053918A1 (en) * 2001-05-16 2005-03-10 Technion Research & Development Foundation Ltd. Method of identifying peptides capable of binding to MHC molecules, peptides identified thereby and their uses
US6685971B2 (en) 2001-06-28 2004-02-03 Rongxiang Xu Method and composition for repairing and promoting regeneration of mucosal tissue in the gastrointestinal tract
CN1827766B (zh) 2001-06-28 2010-08-25 徐荣祥 体外细胞的培养方法
CA2457424A1 (en) 2001-08-03 2003-02-20 Arbor Vita Corporation Molecular interactions in cells
WO2003032964A2 (en) * 2001-10-17 2003-04-24 University Of Wales College Of Medecine Gap junctions and endothelial-derived hyperpolarizing factor (edhf)
JP2003238441A (ja) 2002-02-08 2003-08-27 英行 ▲高▼野 血管新生抑制剤
AU2003234613A1 (en) * 2002-05-15 2003-12-02 Seul, Kyung, Hwan Method of modulating angiogenesis
WO2004073616A2 (en) 2003-02-14 2004-09-02 Human Matrix Sciences Llc Elastin digest compositions and methods utilizing same
SG187381A1 (en) 2003-12-03 2013-02-28 Coda Therapeutics Nz Ltd Antisense compounds targeted to connexins and methods of use thereof
US9408381B2 (en) 2004-12-21 2016-08-09 Musc Foundation For Research Development Alpha Connexin c-Terminal (ACT) peptides for use in transplant
EP1827480B1 (en) * 2004-12-21 2016-11-09 MUSC Foundation For Research Development Compositions and methods for promoting wound healing and tissue regeneration
WO2006134494A2 (en) 2005-02-03 2006-12-21 Coda Therapeutics Limited Anti-connexin compounds and therapeutic uses thereof
JP5552048B2 (ja) 2007-06-21 2014-07-16 ムスク ファンデーション フォー リサーチ ディベロップメント 加齢性黄斑変性を治療するためのアルファコネキシンｃ末端（ａｃｔ）ペプチド
JP5879841B2 (ja) * 2011-09-12 2016-03-08 富士ゼロックス株式会社 画像形成装置
EP2586436A1 (en) * 2011-10-31 2013-05-01 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitor

Also Published As

Publication number Publication date
EP2377546A3 (en) 2012-01-25
US20080095819A1 (en) 2008-04-24
US20170128523A1 (en) 2017-05-11
JP5243040B2 (ja) 2013-07-24
US20090215665A1 (en) 2009-08-27
US8357668B2 (en) 2013-01-22
US8916515B2 (en) 2014-12-23
NO342964B1 (no) 2018-09-10
RU2582394C2 (ru) 2016-04-27
RU2438696C2 (ru) 2012-01-10
US8859733B2 (en) 2014-10-14
US9394351B2 (en) 2016-07-19
CA2593979C (en) 2018-09-18
RU2007127888A (ru) 2009-01-27
ES2620363T3 (es) 2017-06-28
EP2377546A2 (en) 2011-10-19
DK2377546T3 (en) 2017-02-13
US7786074B2 (en) 2010-08-31
US9855313B2 (en) 2018-01-02
US20140038880A1 (en) 2014-02-06
EP2374469A2 (en) 2011-10-12
WO2006069181A2 (en) 2006-06-29
WO2006069181A3 (en) 2007-06-14
US20150140060A1 (en) 2015-05-21
US20130274206A1 (en) 2013-10-17
EP2289535A3 (en) 2011-06-22
IL184045A (en) 2015-08-31
US20130177628A1 (en) 2013-07-11
US8809257B2 (en) 2014-08-19
SG158153A1 (en) 2010-01-29
EP2289535A2 (en) 2011-03-02
AU2005319155A1 (en) 2006-06-29
NZ556541A (en) 2011-01-28
HUE038099T2 (hu) 2018-09-28
JP2008523843A (ja) 2008-07-10
US20110059173A1 (en) 2011-03-10
JP2013136595A (ja) 2013-07-11
CA2593979A1 (en) 2006-06-29
DK1827480T3 (en) 2017-01-09
KR101236450B1 (ko) 2013-02-25
US20180071363A1 (en) 2018-03-15
RU2011139724A (ru) 2013-04-10
PL2289535T3 (pl) 2018-12-31
AU2005319155A2 (en) 2006-06-29
AU2005319155B2 (en) 2013-01-31
EP1827480B1 (en) 2016-11-09
KR20070102998A (ko) 2007-10-22
EP2374469A3 (en) 2012-01-25
EP2289535B1 (en) 2018-03-28
IL206497A (en) 2015-02-26
US7888319B2 (en) 2011-02-15
JP5602891B2 (ja) 2014-10-08
IL184045A0 (en) 2008-12-29
EP2289535B8 (en) 2018-08-08
NO20073654L (no) 2007-09-19
US10398757B2 (en) 2019-09-03
EP2377546B1 (en) 2016-11-02
IL206497A0 (en) 2010-12-30
EP1827480A2 (en) 2007-09-05

Similar Documents

Publication Publication Date Title
BRPI0519737A2 (pt) composiÇÕes e mÉtodos para promover a cura de feridas e a regeneraÇço de tecidos
ATE486860T1 (de) Phenothiazin-derivat zur wundheilung
CL2007002228A1 (es) Composicion farmaceutica topica que comprende 1-(2-metilpropil)-1h-imidazo[4,5-c]quinolin-4-amina; composiicon empacada; metodos para esterelizarlas; util para cicatrizar tejido donde la dermis se ha desgarrado.
CL2007002095A1 (es) Composicion farmaceutica topica que comprende 1-(2-metilpropil)-1h-imidazo[4,5-c]quinolin-4-amina; composicion empacada; metodo para esterilizarla; util para cicatrizar tejido donde la dermis se ha desgarrado.
BRPI0721905B8 (pt) composto inibidor de proteassoma, sua composição farmacêutica e seu uso
SE0401300D0 (sv) Novel Galactoside Inhibitors of Galectins
CL2008001171A1 (es) Composicion farmaceutica que comprende fibrinogeno, trombina y un compuesto que contiene estroncio; y su uso en el tratamiento de un hueso enfermo, dañado, deficiente o defectuoso.
BR112012008854A2 (pt) combinação, kit de combinação, uso de uma combinação, composição farmacêutica, e, método para tratar câncer em um ser humano
ECSP11010948A (es) Inhibidores de las enzimas de proteína cinasa activadas por
BRPI0812638A2 (pt) "método para diminuir a pressão em um indivíduo método para reduzir inflamação vascular em um indivíduo, composição farmacêutica para diminuira pressão sanguínea em um indivíduo e uso de uma composição"
CL2009001484A1 (es) Sal glicinato de metformina; composición farmacéutica que comprende la sal; y su uso para tratar la hiperglicemia.
CL2008000893A1 (es) Composición para el cuidado bucal que comprende una cantidad efectiva de un aminoácido básico y un agente antibacteriano; uso en el tratamiento antibacteriano de la cavidad bucal.
UY31272A1 (es) Nuevos derivados de ácido azabifenilaminobenzoico
ATE395924T1 (de) Wiederherstellung zerstörten gewebes mit hilfe von multipotenten zellen
BRPI0912292A2 (pt) composições e métodos para o uso de células no tratamento do tecido cardíaco.
BR0009158B1 (pt) composição tópica baseada em ácido ascórbico para o tratamento de danos na pele
ECSP088452A (es) Composiciones y métodos para modular la hemostasia
EA200802364A1 (ru) Композиция для ухода за кожей и ее применение
CL2008002089A1 (es) Compuesto para la regeneracion de tejidos que comprende al menos una sustancia derivada de sangre y acido hialuronico y/o al menos un compuesto derivado de acido hialuronico; metodo para la prepararcion de dicho compuesto.
WO2007030666A3 (en) Medicated skin care preparation for promoting wound healing
EP1919502A4 (en) PROTEIN COMPOSITIONS FOR HEALING OF LESIONS AND SKIN REGENERATION
ZA200706016B (en) Compositions and methods for promoting wound healing and tissue regeneration
ECSP088884A (es) Compuestos heterociclicos fusionados y su uso como moduladores de mglur5
CL2009001804A1 (es) Uso de un copolimero de vinilamina-vinilformamida y un portador para preparar una composicion destinada a fortalecer las fibras queratinosas.
UY29434A1 (es) Derivados de tetrahidronaftalina, procedimientos para su preparación y su uso como inhibidores de la inflamacinn

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL